Daily Endocrinology Research Analysis
Analyzed 38 papers and selected 3 impactful papers.
Summary
Three mechanistic and translational studies redefine endocrine-metabolic crosstalk. Adipocytic sclerostin loop3-LRP4 signaling emerges as a modifiable node to improve lipid and glucose metabolism, endothelial FUNDC1 is identified as a vascular driver of the obesity-to-diabetes transition via the SIRT3/GATA2/ET-1 axis, and MASLD is shown to accelerate PDAC progression through a targetable MIF–CD44 pathway.
Research Themes
- Vasculature–metabolism crosstalk driving insulin resistance
- Bone–adipose endocrine signaling influencing systemic metabolism
- Metabolic liver disease fueling cancer metastasis via immunomodulation
Selected Articles
1. Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.
Serum sclerostin was elevated in POP with T2DM and in newly diagnosed T2DM. Blocking adipocyte-specific sclerostin loop3-LRP4 interactions ameliorated sclerostin-induced dyslipidemia and dysglycemia in vitro and in vivo, suggesting a therapeutically distinct and potentially cardiovascularly safer approach than loop2-directed antibodies.
Impact: Identifies an adipose-specific sclerostin mechanism driving systemic metabolic dysfunction and offers a precise, safety-conscious target distinct from current anti-sclerostin therapies.
Clinical Implications: Supports development of loop3-LRP4–selective sclerostin inhibitors to improve glucose and lipid metabolism in patients with POP and T2DM while potentially mitigating cardiovascular risk seen with current agents.
Key Findings
- Serum sclerostin levels are elevated in POP with T2DM and in newly diagnosed T2DM.
- Sclerostin loop3 contributes to whole-body lipid and glucose metabolic impairment in vivo.
- Blocking adipocytic sclerostin loop3–LRP4 interaction reverses sclerostin-induced metabolic defects in vitro and in vivo.
Methodological Strengths
- Integrated human data with mechanistic in vitro and in vivo models to establish causality.
- Target-specific intervention (loop3–LRP4 blockade) provides mechanistic precision.
Limitations
- Preclinical nature without randomized clinical trials; human efficacy and safety remain to be established.
- Potential off-target effects and long-term metabolic/osteoskeletal consequences of loop3-specific inhibition are unknown.
Future Directions: Develop selective loop3-LRP4 antagonists, assess metabolic efficacy and cardiovascular safety in large animal models, and progress to early-phase human trials in POP with T2DM.
Sclerostin, which has three loops, inhibits bone formation and impairs whole-body lipid and glucose metabolism. The marketed therapeutic sclerostin antibody for postmenopausal osteoporosis (POP) mainly targeting loop2 promotes bone formation and improves whole-body lipid and glucose metabolism. However, FDA/EMA warns of its cardiovascular risk. We previously demonstrate that sclerostin loop3 contributes to the inhibitory effect of sclerostin on bone formation but not its cardioprotective effect. Here we find elevated serum sclerostin levels in both POP-T2DM patients and newly-diagnosed T2DM patients and further demonstrate that sclerostin loop3 participates in the impairment effect of sclerostin on whole-body lipid and glucose metabolism in vivo. Mechanistically, specific blockade of adipocytic sclerostin loop3-LRP4 interaction attenuates the impairment effect of sclerostin on lipid and glucose metabolism in vitro and in vivo. This study provides an innovative strategy, blocking adipocytic sclerostin loop3-LRP4 interaction, to normalize lipid and glucose metabolism in POP-T2DM patients, in cardiovascular safety.
2. Endothelial FUNDC1 regulates metabolic reprogramming and the obesity-diabetes transition through the SIRT3/GATA2/endothelin-1 axis.
Endothelial FUNDC1 is upregulated in T2DM and under overnutrition and drives a SIRT3-L nuclear export program that increases GATA2 activity and ET-1 production. EC-specific FUNDC1 deletion protects mice from HFD-induced obesity and insulin resistance and aligns with human data linking endothelial FUNDC1 to circulating ET-1.
Impact: Reveals an endothelial mitochondria-to-nucleus signaling axis that causally links vascular stress to systemic metabolic disease, nominating FUNDC1 and ET-1 signaling as druggable nodes.
Clinical Implications: Suggests therapeutic strategies that inhibit endothelial FUNDC1 signaling or retain nuclear SIRT3-L to lower ET-1 and mitigate insulin resistance, informing cardio-metabolic disease prevention.
Key Findings
- Endothelial FUNDC1 expression is elevated in diabetic conditions and correlates with plasma ET-1 in obese/T2DM patients.
- EC-specific Fundc1 deletion protects mice from HFD-induced obesity, insulin resistance, and metabolic disorders.
- Overnutrition triggers FUNDC1-dependent nuclear export of SIRT3-L, disinhibiting GATA2 and enhancing ET-1 production.
Methodological Strengths
- Multi-system approach spanning EC-specific knockout mice, primary and HUVEC models, and human vascular tissues.
- Mechanistic chain elucidation (FUNDC1–SIRT3-L–GATA2–ET-1) with functional metabolic readouts.
Limitations
- Preclinical work without pharmacologic inhibition of FUNDC1 tested in vivo; translatability needs clinical validation.
- Potential sex- and tissue-specific differences were not fully delineated.
Future Directions: Develop small-molecule or biologic inhibitors of FUNDC1 signaling, test ET-1 modulation strategies, and evaluate endothelial-targeted interventions in early human metabolic disease.
Endothelial cell (EC) dysfunction is a hallmark of obesity and Type 2 diabetes mellitus (T2DM), yet the mechanisms linking vascular stress to systemic metabolic diseases remain unclear. Here, we investigated the role of the mitochondrial protein FUN14 domain-containing 1 (FUNDC1) in EC under nutritional overload. Using high-fat diet (HFD)-fed EC-specific Fundc1 knockout mice, human umbilical vein ECs, primary ECs, and vascular tissues from patients with obese/T2DM, we find that endothelial FUNDC1 expression is elevated under diabetic conditions, whereas its deletion protects mice from HFD-induced obesity, insulin resistance, and metabolic disorders. Mechanistically, overnutrition triggers nuclear export of the long isoform of SIRT3 (SIRT3-L) to mitochondria via FUNDC1, disinhibiting GATA2 and enhancing endothelin-1 (ET-1) production. Loss of FUNDC1 in ECs retains SIRT3-L in the nucleus, promoting GATA2 degradation and reducing ET-1. Endothelial FUNDC1 levels correlated positively with plasma ET-1 in individuals with obesity/T2DM. These findings identify endothelial FUNDC1 as a key regulator of vasculature-metabolic organ cross talks and obesity-diabetes transition.
3. Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis.
Across a population-scale cohort and experimental models, MASLD substantially increases PDAC risk and promotes liver metastasis via a MIF–CD44 pathway that augments tumor stemness, immune evasion, and adhesion. Pharmacologic MIF inhibition (IPG1576) attenuated liver metastasis, nominating a translationally actionable target.
Impact: Bridges epidemiology and mechanism to implicate a druggable axis in MASLD-driven PDAC metastasis, informing risk stratification and targeted intervention for a lethal cancer.
Clinical Implications: MASLD status should inform PDAC risk assessment and surveillance; the MIF–CD44 axis is a candidate for therapeutic targeting to prevent or treat liver metastasis, warranting clinical trials of MIF inhibitors.
Key Findings
- MASLD is associated with increased PDAC risk in UK Biobank (HR 3.48; 95% CI 2.69–4.50).
- Clinical cohorts show strong association between MASLD and hepatic metastases (OR 7.06; 95% CI 4.62–10.78).
- MIF secretion promotes CD44+ PDAC cell migration, stemness, and adhesion; MIF inhibition (IPG1576) attenuates liver metastasis in preclinical models.
Methodological Strengths
- Large prospective cohort (UK Biobank) integrated with clinical cohorts and mechanistic mouse models.
- Demonstration of targetability using genetic and pharmacologic MIF inhibition with concordant patient tissue validation.
Limitations
- Observational associations may be subject to residual confounding despite adjustment.
- Preclinical efficacy of IPG1576 requires safety and dosing evaluation in humans; generalizability across ethnicities and MASLD severities needs study.
Future Directions: Prospective stratified PDAC surveillance in MASLD populations and early-phase trials of MIF inhibitors alone or combined with chemotherapy/immunotherapy to prevent or treat liver metastasis.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis, particularly in the presence of liver metastases. The mechanisms by which metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), influences PDAC progression and metastasis remain poorly understood. This study investigates the role of MASLD in fostering an immunosuppressive microenvironment conducive to PDAC liver metastases and identifies the macrophage migration inhibitory factor (MIF)-CD44 axis as a key mediator of this process. Utilizing data from the UK Biobank (450,754 participants, median follow-up 14.5 years), we observed an overall increased risk of PDAC in the MASLD population (HR: 3.48; 95% CI: 2.69-4.50; P < 0.0001). Clinical cohorts confirmed the strong association between MASLD and hepatic metastases (OR: 7.06; 95% CI: 4.62-10.78; P < 0.0001). Experimental mouse models demonstrated that MASLD enhances tumor cell stemness, immune evasion, and focal adhesion in metastatic liver tissues. Mechanistically, MASLD-induced MIF secretion promotes CD44-positive PDAC cell migration, stemness, and adhesion. Targeting MIF, either genetically or pharmacologically using the MIF tautomerase inhibitor IPG1576 significantly attenuated liver metastasis in preclinical models. Validation in patient samples revealed elevated hepatic MIF and CD44 expression in MASLD-associated PDAC liver metastases. This study highlights the MIF-CD44 axis as a promising therapeutic target and underscores the importance of tailoring treatments for PDAC patients with concurrent MASLD.